49例MALT淋巴瘤临床资料分析

本研究旨在探讨黏膜相关淋巴组织淋巴瘤（mucosa-associated lymphoid tissue lymphoma，MALTlymphoma）临床特点、APl2．MALTl基因的表达与预后的关系。通过回顾临床资料，研究我院49例MALT淋巴瘤患者的临床特点，并通过RT．PCR法检测部分石蜡标本APl2．MALTl基因重排。结果表明：MALT淋巴瘤患者的发病平均年龄为52，4岁，50岁以上的患者占67．4％，肿瘤多发生在胃肠道，其次在甲状腺；49例中I、Ⅱ期患者占776．％，Ⅲ、IV期患者占22．4％；APl2-MALTl基因重排在低度恶性组、转化组的阳性率分别为38．1％和12、5％；3年生存率为93．8％。结论：MALT淋巴瘤患者的临床进展缓慢，对化疗敏感，预后较好，可根据有无APl2-MALTl基因重排选择不同的治疗方法，对I期HP阳性患者可采用抗HP治疗。

Analysis of Prognostic Correlated Factors of 49 Patients with Mucosa-associated Lymphoid Tissue Lymphoma

The aim of this study was to investigate the clinical feature of mucosa-associated lymphoid tissue lymphoma and clarify the relationship between the pathological, clinical features, the expression of API2-MALT1 and the prognosis. A number of factors including pathological characters, grade, stage, prognosis and treatment of 49 cases of MALT lymphoma were analyzed, and the API2-MALT1 rearrangement was detected by RT-PCR. The results showed that 49 patients were diagnosed as MALT lymphoma, in which median age was 52.4 years. The percentage of patients older than 50 years was 67.3%. The majority of tumors were found in stomach (22 cases), intestine (13 cases), thyroid (6 cases) and so on. Among 49 patients, stage I, II was 77. 6%, stage III, IV was 22.4%. API2-MALT1 rearrangement were found 38.1% in low grade, and 12.5% in transform type. Among 18 patients with gastric MALT lymphoma, 9 cases (50.0%) were helicobacter pylori (HP) positive and received antibiotic treatment. The 3 years overall survival was 93.8%. It is concluded that MALT lymphoma is often seen in older patients, most of them were in low grade with slow progression. The site, grade, stage and molecular genetic changes are important prognostic factors, which can contribute to choosing suitable treatment for patients with MALT lymphoma. The antibiotic treatment is effective for patients with positive HP.